Purpose: To assess quality-of-life and work productivity outcomes for patients with Crohn's disease (CD) who received high-dose infliximab (IFX) prior to entering an adalimumab (ADA) clinical trial for CD. Methods: Data from 3 open-label clinical trials of ADA for CD were reviewed: ACCESS, CARE, and CHOICE. High-dose IFX was defined as a maintenance dosage greater than the recommended initial dosage for CD (ie, ≥7 mg/kg) or a shorter dosing interval (ie, ≤every 6 weeks). Paired Wilcoxon signed-rank tests were used to compare Short Inflammatory Bowel Disease Questionnaire (SIBDQ) and Work Productivity and Activity Impairment Questionnaire (WPAI) scores between baseline and each follow-up visit for all patients with prior high-dose IFX maintenance therapy who received ADA 160-/80-mg induction therapy followed by ADA 40-mg every-other-week (eow) maintenance therapy during the trial. For patients who switched from ADA eow to ADA weekly, the last observations at the time patients changed to weekly therapy were carried forward to impute the outcome values. Subgroup analyses for patients who responded well but discontinued IFX owing to intolerance were conducted for CHOICE. Because of the small sample size, the subgroup analysis was not conducted for ACCESS or CARE. Results: SIBDQ and WPAI scores at study endpoint for high-dose IFX users who received ADA 40 mg eow as maintenance therapy improved significantly from baseline (table). Results were similar for the subgroup of patients who responded initially but developed intolerance to IFX in CHOICE. Conclusion: After receiving treatment with ADA 160/80 induction followed by ADA eow maintenance therapy, patients with prior high-dose IFX therapy experienced significant improvements in patient-reported outcomes. Disclosure: R Panaccione: Consultant: Abbott, AstraZeneca, Ferring, Schering-Plough, Shire, Centocor, Elan, Glaxo-Smith Kline, UCB, Proctor and Gamble, Bristol Myers Squibb. Speaker's Fees: Abbott, AstraZeneca, Byk Solvay, Axcan, Jansen, Schering-Plough, Shire, Centocor, Elan, Prometheus, Proctor and Gamble. Advisory Boards: Abbott, Ferring, Schering-Plough, Shire, Elan, Proctor and Gamble. Research/Educational Support: Abbott, Ferring, Axcan, Jansen, Schering-Plough, Centocor, Millennium, Elan, Proctor and Gamble, Bristol Myers Squibb. E Louis: Grant/Research Support: AstraZeneca, Schering-Plough. Speaker's Fees: AstraZeneca, UCB, Abbott, Schering-Plough, Ferring. Advisory Boards: Abbott, UCB, Ferring. DG Binion: Speaker's Fees: Abbott Laboratories, Centocor, Elan, Procter & Gamble, Prometheus, Salix, Shire, UCB. Grant/Research Support: National Institute of Health, Centocor, Elan, Biogen, Procter & Gamble. M Yang: Employee/Stock: Abbott N Chen: Employee/Stock: Abbott KG Lomax: Employee/Stock: Abbott PM Mulani: Employee/Stock: Abbott J Chao: Employee/Stock: Abbott.Table: [1192] Mean changes in SIBDQ and WPAI from baseline to study endpoint a